DeQuervain's TenosynovitisNCT07683429
Local Corticosteroid Injection Versus Open Surgical Release in De Quervain Tenosynovitis: A Single-Center Study
A study testing Triamcinolone acetonide with lidocaine and Open surgical release of first dorsal extensor compartment in people with DeQuervain's Tenosynovitis, run by Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi at 1 site in Pakistan.
Trial summary
This quasi-experimental study compared pain outcomes following local corticosteroid injection (CSI) versus open surgical release in 100 patients with clinically confirmed De Quervain tenosynovitis unresponsive to conservative management. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- DeQuervain's Tenosynovitis
- What is being tested?
- Triamcinolone acetonide with lidocaine and Open surgical release of first dorsal extensor compartment
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 sitePakistan
- Study dates
- 3 Mar 2023to 20 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical diagnosis of De Quervain tenosynovitis confirmed by positive Finkelstein test
- Age 18-70 years
- Pain sufficiently severe to impair activities of daily living
- Failure to respond to at least 4 weeks of conservative management
Who cannot join
- Concurrent inflammatory arthropathy (rheumatoid arthritis or gout)
- History of prior wrist injury
- Previous surgical or injection treatment for De Quervain tenosynovitis
- Coexisting upper limb pathology (rotator cuff pathology, epicondylitis, or carpal tunnel syndrome)
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Rawalpindi Teaching Hospital.
Rawalpindi, Punjab Province, 46000
About this study
Official title: Comparative Effectiveness of Local Corticosteroid Injection and Open Surgical Release for Pain Outcomes in De Quervain Tenosynovitis: A Single-Centre Study
This quasi-experimental study compared pain outcomes following local corticosteroid injection (CSI) versus open surgical release in 100 patients with clinically confirmed De Quervain tenosynovitis unresponsive to conservative management. Patients were allocated to treatment based on clinician judgment and patient preference. Pain was assessed using the Visual Analog Scale (VAS) at baseline, one month, and six months post-intervention. The study was conducted at a single tertiary care centre in Rawalpindi, Pakistan between March 2023 and April 2025.
Read the detailed description
De Quervain tenosynovitis is a stenosing tendinopathy of the first dorsal extensor compartment of the wrist, causing radial-sided wrist pain. One hundred patients were enrolled and allocated to either corticosteroid injection (CSI; n=49) or open surgical release (n=51). The CSI protocol consisted of triamcinolone acetonide (40mg/mL, 1mL) combined with 1% lidocaine (1mL) injected into the first dorsal compartment under aseptic conditions. Surgical release involved longitudinal decompression of the fibro-osseous sheath overlying the APL and EPB tendons. The primary outcome was VAS pain score at baseline, one month, and six months. Statistical analysis included independent t-tests and linear mixed-effects modeling.
- Conditions
- DeQuervain's Tenosynovitis
- Being tested
- Triamcinolone acetonide with lidocaine, Open surgical release of first dorsal extensor compartment
- Keywords
- De Quervain tenosynovitis, tendinopathy, corticosteroid injection, quasi-experimental study; wrist, surgical release, visual analog scale
- Medical subject headings
- De Quervain Disease, Tendinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Triamcinolone acetonide with lidocaineDrug
Triamcinolone acetonide 40mg/mL (1mL) + 1% lidocaine (1mL) - single injection
Open surgical release of first dorsal extensor compartmentProcedure or surgery
Longitudinal decompression of the fibro-osseous sheath overlying APL and EPB tendons
| Study group | Role | What they receive |
|---|---|---|
| Corticosteroid Injection (CSI) | Active comparator | Single injection of triamcinolone acetonide (40mg/mL, 1mL) combined with 1% lidocaine (1mL) administered into the first dorsal extensor compartment under aseptic conditions without ultrasound guidance. Receives: Drug: Triamcinolone acetonide with lidocaine |
| Open Surgical Release | Active comparator | Open decompression of the first dorsal compartment through a longitudinal incision over the radial styloid, with release of the fibro-osseous sheath overlying the APL and EPB tendons, closed with non-absorbable sutures. Receives: Procedure: Open surgical release of first dorsal extensor compartment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain intensity - Visual Analog Scale (VAS)
Pain scored on a 0-10 VAS scale where 0 = no pain and 10 = worst imaginable pain, assessed by a blinded assessor
Measured: Time Frame: Baseline, 1 month, and 6 months post-intervention
Secondary outcomes (1)
Adverse events
Any complications or adverse events recorded in either treatment group
Measured: Throughout 6-month follow-up period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2026
- Study start3 Mar 2023
- Primary completion3 Apr 2025
- Study completion20 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DeQuervain's TenosynovitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Osama Ijaz, Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi
- Investigators
- Saad Riaz, FCPS Orthopedic Surgery, Study chair, Rawalpindi Teaching Hospital.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07683429
- Sponsor's protocol ID
- RTH-DQT-2023
- Status last verified
- Jun 2026
- First submitted
- 27 Jun 2026
- Last updated
- 6 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data are not publicly available due to institutional privacy policies but are available from the corresponding author upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Effectiveness of Local Corticosteroid Injection and Open Surgical Release for Pain Outcomes in De Quervain Tenosynovitis: A Single-Centre Study
- ClinicalTrials.gov ID
- NCT07683429
- Acronym / sponsor ID
- RTH-DQT-2023
- Conditions
- DeQuervain's Tenosynovitis
- Keywords
- De Quervain tenosynovitis, tendinopathy, corticosteroid injection, quasi-experimental study; wrist, surgical release, visual analog scale
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Rawalpindi Teaching Hospital, District Headquarter Hospital, RawalpindiOther government
- Study start
- 3 Mar 2023 (actual)
- Primary completion
- 3 Apr 2025 (actual)
- Study completion
- 20 Apr 2025 (actual)
- First posted
- 6 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This quasi-experimental study compared pain outcomes following local corticosteroid injection (CSI) versus open surgical release in 100 patients with clinically confirmed De Quervain tenosynovitis unresponsive to conservative management. Patients were allocated to treatment based on clinician judgment and patient preference. Pain was assessed using the Visual Analog Scale (VAS) at baseline, one month, and six months post-intervention. The study was conducted at a single tertiary care centre in Rawalpindi, Pakistan between March 2023 and April 2025.
Detailed description
De Quervain tenosynovitis is a stenosing tendinopathy of the first dorsal extensor compartment of the wrist, causing radial-sided wrist pain. One hundred patients were enrolled and allocated to either corticosteroid injection (CSI; n=49) or open surgical release (n=51). The CSI protocol consisted of triamcinolone acetonide (40mg/mL, 1mL) combined with 1% lidocaine (1mL) injected into the first dorsal compartment under aseptic conditions. Surgical release involved longitudinal decompression of the fibro-osseous sheath overlying the APL and EPB tendons. The primary outcome was VAS pain score at baseline, one month, and six months. Statistical analysis included independent t-tests and linear mixed-effects modeling.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Corticosteroid Injection (CSI) | Active comparator | Drug: Triamcinolone acetonide with lidocaineSingle injection of triamcinolone acetonide (40mg/mL, 1mL) combined with 1% lidocaine (1mL) administered into the first dorsal extensor compartment under aseptic conditions without ultrasound guidance. |
| Open Surgical Release | Active comparator | Procedure: Open surgical release of first dorsal extensor compartmentOpen decompression of the first dorsal compartment through a longitudinal incision over the radial styloid, with release of the fibro-osseous sheath overlying the APL and EPB tendons, closed with non-absorbable sutures. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Clinical diagnosis of De Quervain tenosynovitis confirmed by positive Finkelstein test
- Age 18-70 years
- Pain sufficiently severe to impair activities of daily living
- Failure to respond to at least 4 weeks of conservative management
Key exclusion criteria (4 listed)
- Concurrent inflammatory arthropathy (rheumatoid arthritis or gout)
- History of prior wrist injury
- Previous surgical or injection treatment for De Quervain tenosynovitis
- Coexisting upper limb pathology (rotator cuff pathology, epicondylitis, or carpal tunnel syndrome)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Triamcinolone acetonide with lidocaineTriamcinolone acetonide 40mg/mL (1mL) + 1% lidocaine (1mL) - single injection | Drug | Corticosteroid Injection (CSI) |
| Open surgical release of first dorsal extensor compartmentLongitudinal decompression of the fibro-osseous sheath overlying APL and EPB tendons | Procedure or surgery | Open Surgical Release |
Primary outcome
Pain intensity - Visual Analog Scale (VAS)
Time frame: Time Frame: Baseline, 1 month, and 6 months post-intervention
Pain scored on a 0-10 VAS scale where 0 = no pain and 10 = worst imaginable pain, assessed by a blinded assessor
1 secondary outcome
Adverse events
Time frame: Throughout 6-month follow-up period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data are not publicly available due to institutional privacy policies but are available from the corresponding author upon reasonable request.
Related trials for DeQuervain's Tenosynovitis
Not yet recruitingObservational study
Early Functional Response as a Predictor of Clinical Outcomes in Hand Rehabilitation: A Prospective Feasibility Study Using a Digital Monitoring System
Hand, Hand Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Saad Riaz, FCPS Orthopedic Surgery study chair
Rawalpindi Teaching Hospital.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Triamcinolone acetonide with lidocaine and Open surgical release of first dorsal extensor compartment in people with DeQuervain's Tenosynovitis, run by Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain intensity - Visual Analog Scale (VAS) (time frame: Time Frame: Baseline, 1 month, and 6 months post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.